Related Experiment Video
Updated: Mar 16, 2026
08:04
Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
1.7K
Epilepsy beyond seizures: Predicting enduring cognitive dysfunction in genetic generalized epilepsies.
Amy Loughman1, Udaya Seneviratne2, Stephen C Bowden3
1Melbourne School of Psychological Sciences, University of Melbourne, Parkville, VIC 3010, Australia.
Epilepsy & Behavior : E&B
|August 22, 2016
Summary
In genetic generalized epilepsies (GGE), the duration of epileptiform discharges significantly impacts cognitive function and memory. These discharges are common and often unnoticed by patients, highlighting a critical area for GGE management.
Area of Science:
- Neurology
- Neuropsychology
- Epileptology
Background:
- Reduced cognitive functioning is a known issue in genetic generalized epilepsies (GGE).
- Epileptiform discharges are hypothesized as a potential cause of cognitive impairment in epilepsy.
Purpose of the Study:
- To investigate the relationship between the burden of epileptiform discharges and cognitive function in GGE patients.
- To control for other relevant variables affecting cognition in epilepsy.
Main Methods:
- A prospective cohort study included 69 GGE patients (aged 11-58).
- 24-hour EEG recordings and neuropsychological assessments (Woodcock Johnson III Tests) were performed.
- Manual EEG analysis and multiple regression were used to analyze data.
Main Results:
- Epileptiform discharges were present in 90% of patients.
- The cumulative duration of epileptiform discharges predicted overall cognitive ability (9.6% variance) and memory function (11.8% variance).
- Epilepsy covariates did not significantly add to the predictive model.
Conclusions:
- Prolonged epileptiform discharges negatively impact cognitive ability and memory in GGE, independent of other factors.
- These discharges are frequent and often unrecognized by patients, suggesting a need for revised management strategies.
- Further research is needed to understand causal mechanisms and improve cognitive outcomes in GGE.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
1.6K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.6K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
01:20Antiepileptic Drugs: Potassium Channel Activators
895
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
895
01:14Antiepileptic Drugs: Glutamate Antagonists
1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
01:13Seizures: Classification
2.0K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.0K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K